Halifax's Immunovaccine Obtains $5M Debt Financing

Halifax, Nova Scotia-based Immunovaccine Inc. (TSX-V: IMV), a clinical stage vaccine developer, has obtained a secured loan of $5 million from the provincial government. The debt financing will be used to fund a portion of working capital for clinical development through 2016. Founded in 2007, Immunovaccine has in past received private placements from various sources, including the Atlantic Canada Opportunities Agency.

CanadaNorth AmericaBriefs